Rate Video

VJVirtual | ANNOUNCE: doxorubicin + olaratumab in advanced soft tissue sarcomas

Robin Jones • 28 Apr 2020

Sarcoma Doxorubicin Olaratumab

Robin Jones, MBBS, MRCP, MD (Res), Royal Marsden NHS Foundation Trust, London, UK, updates us on recent results published from the ANNOUNCE Phase III study which evaluated the addition of olaratumab to doxorubicin in patients with advanced/metastatic soft tissue sarcoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Challenges of desmoid tumors

Robin Jones • 1 Nov 2022

Unmet needs in desmoid tumors

Robin Jones • 1 Nov 2022

Update on the NAVIGATOR study

Robin Jones • 23 Sep 2020

The advantages of face-to-face meetings

Robin Jones • 9 Feb 2022

Related Videos

Trabectedin and pazopanib: an indirect comparison of their ability to treat LMS

How has the trabectedin extended access program benefited sarcoma patients?

The current state of drug development against sarcomas

Response rates to immunotherapy in sarcoma patients and implications for future therapies

Gary Schwartz • 3 Jun 2016